Merck
Merck is providing refunds for 340B overcharges during Q4 2019, Q3 2021, and Q2 2022.

Merck Providing Refunds for 340B Overcharges During Q4 2019, Q3 2021, and Q2 2022

Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.

The U.S. Health Resources and Services Administration posted Merck’s Nov. 21 notice about the repayments on its website late last week. Merck said the refunds are due to revised pricing data submitted to the Centers for Medicare & Medicaid Services.

Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts